https://www.cantechletter.com/2026/05/this-analyst-just-upped-his-price-target-on-knight-therapeutics/Cantech Letteren2026-05-08T12:05:16-03:00This analyst just upped his price target on Knight Therapeutics https://www.cantechletter.com/2026/05/kinaxis-is-rolling-this-analyst-says/Cantech Letteren2026-05-08T11:01:26-03:00Kinaxis is rolling, this analyst says https://www.cantechletter.com/2026/05/this-analyst-just-raised-his-price-target-on-curaleaf/Cantech Letteren2026-05-08T10:08:57-03:00This analyst just raised his price target on Curaleaf https://www.cantechletter.com/2026/05/buy-this-pot-stock-for-a-double-analyst-says-2/Cantech Letteren2026-05-07T13:22:19-03:00Buy this pot stock for a double, analyst says https://www.cantechletter.com/2026/05/cryoport-stock-is-a-buy-this-analyst-says/Cantech Letteren2026-05-07T11:36:39-03:00Cryoport stock is a buy, this analyst says https://www.cantechletter.com/2026/05/eupraxia-wins-new-us-15-50-target-at-leede-financial/Cantech Letteren2026-05-07T09:53:02-03:00Eupraxia wins new (US) $15.50 target at Leede Financial https://www.cantechletter.com/2026/05/thinkific-labs-buy-sell-or-hold/Cantech Letteren2026-05-07T09:42:12-03:00Thinkific Labs: Buy, Sell or Hold?